<?xml version="1.0" encoding="UTF-8"?>
<p>Nowadays, there are no U.S. Food and Drug Administration (FDA) granted antivirals [
 <xref rid="B14-viruses-12-00122" ref-type="bibr">14</xref>], vaccines, or immunotherapeutic for the treatment of HFRS or HPS, and consequently, therapeutic approaches are usually based on supportive care. It is precisely for that reason that an effort to develop potential therapeutic agents is strongly desirable. At the present time, a very limited number of antivirals have been tested for orthohantavirus [
 <xref rid="B14-viruses-12-00122" ref-type="bibr">14</xref>]. 
</p>
